Indeed, the cut-offs values for MYC and BCL2 positivity evaluated by pathologists are still a matter of debate, but recent studies reported prevalence of double expressor DLBCL cases ranging from 21 to 31%24,26–29. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.